MERCK AG ACQUIRES PROLABO FRANCE
Laboratoires Merck-Clevenot, the French arm of the Swiss-based pharmaceutical company Merck AG, has acquired Prolabo of France, which was previously part of the Rhone-Poulenc group. The acquisition is subject to approval by French authorities.
Prolabo manufactures reagents, along with its subsidiary Cofralab which is based in Bordeaux, and is a leading trading company for laboratory products and systems, according to Merck. The company's consolidated sales in 1992 were 150 million Swiss francs ($101.2 million), and it employs around 500 staff.
Merck intends to expand its laboratory products division via this acquisition. In 1991 the division's sales amounted to around 650 million Swiss francs, or around 30% of the group's entire sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze